ClinicalTrials.gg
RecruitingNCT06486792SPICAFUpdated Jun 5, 2026

Stroke Prevention In Ischemic Stroke With Covert Atrial Fibrillation

A Phase 4 interventional study of Apixaban and Aspirin in Stroke, Ischemic Stroke and Cerebral Infarction, sponsored by Assistance Publique - Hôpitaux de Paris. Recruiting at 1 site in France. Open to participants aged 65 Years and older. Per ClinicalTrials.gov, last updated 2026-06-05.

Sponsored by Assistance Publique - Hôpitaux de Paris · Phase 4, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jun 2025; still recruiting 1 year 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
1,148
Allocation
Randomized
Ages
65 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 11 studies testing apixaban in Stroke — 5 open to participants now, 5 under way, 3 of them phase 3. apixaban · Stroke.

Planned enrollment
4th of 11
1,148 · median 840
Started
2025
with 1 other
Phase 4
4 of 11
2 open now
Registered
9th of 11
by date
Lead sponsor
2 of 11
Assistance Publique - Hôpitaux de Paris

Among the 11 studies testing apixaban in Stroke, this one is the 4th largest by planned enrollment, is one of 2 that started in 2025, is one of 4 in phase 4, and was the 9th registered.

Stroke

8,283 studies on the registry are indexed under Stroke; 2,065 are open to participants now.

Browse Stroke studies →

Open to participants now

5 of the 11 studies testing apixaban in Stroke are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About apixaban

apixaban: first FDA approval 2012 (ELIQUIS), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,418 Stroke studies recruiting now, 698 (49%) set no upper age limit and 281 (20%) stop at 75 or younger; 77 take children under 18; 197 take healthy volunteers.

This study: 65 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies testing apixaban in Stroke, or all of them as a file.
02

Study summary

Patients who have recently had an ischemic stroke with no clear cause might have undetected atrial fibrillation (AF) that isn't caught during their initial hospital stay. After discharge, these patients are typically monitored for AF using devices like Holter monitors or implantable loop recorders. Treatment options during this period include anticoagulants or aspirin. Anticoagulants are more effective in preventing recurrent strokes if AF is present, offering an 80% risk reduction compared to aspirin's 20%. If AF is detected, anticoagulant treatment continues; if not, patients may switch to aspirin after 6-12 months. Despite the clinical rationale for using anticoagulants during this search period, their benefit-risk ratio compared to aspirin has not been fully evaluated.

Read the detailed description

Patients with recent ischemic stroke with an unknown cause may have a clinical, radiological and echocardiographic pattern of covert atrial fibrillation which is yet undetected by history, ECG monitoring or telemetry during the initial hospital stay. These patients are usually discharged with a prescription of detection of atrial fibrillation in the next weeks by either Holter ECG monitoring, or loop recorder such as wearing device or implantable device. Current standard treatment for these patients is either using anticoagulant treatment during the time of atrial fibrillation search or simply aspirin with the risk that the patient has an undetected paroxysmal atrial fibrillation with a high risk of recurrent stroke that is less prevented by aspirin (20% RRR) than by anticoagulant (80% RRR). Anticoagulant treatment in this situation is clinically justified by the fact that if the patient actually has an atrial fibrillation, an anticoagulant treatment during the search period of AF will protect the patient from a recurrent stroke, rather than treating the patient after the discovery of AF with the risk that an AF-related recurrent stroke occurs in-between. Anticoagulant treatment is then continued if atrial fibrillation is demonstrated by monitory devices, or is stopped with a switch to aspirin after 6-12 months of negative AF search, since investigators know, after NAVIGATE-ESUS and RESPECT-ESUS trials, that long-term aspirin is safer and as effective as anticoagulant in case of cryptogenic stroke.

Although anticoagulant treatment during the search period for AF makes clinically sense, and is widely used in clinical practice, its benefit/risk ratio compared to aspirin therapy has not been evaluated

03

Conditions studied

  • Stroke
  • Ischemic Stroke
  • Cerebral Infarction
  • Atrial Fibrillation

Keywords

  • Stroke
  • Ischemic Stroke
  • Cerebral infarction
  • Atrial Fibrillation
  • Anticoagulant
  • Aspirin
  • Prevention stroke
  • AVK
  • Apixaban
  • rivaroxaban
  • dabigatran
  • ECG
04

Who can participate

Ages eligible
65 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Included patients must fulfill the following 4 criteria:

  1. patient aged ≥65 years with:

    1. recent (\<15 days) cerebral infarction
    2. with cerebral ischemia proven on MRI or head-CT
  2. with no known atrial fibrillation before stroke and no atrial fibrillation detected during hospital stay (monitoring or telemetry) and no mural thrombus.
  3. but with suspected atrial fibrillation:

    1. multiple territorial (i.e., in the territory of a cerebral artery or one of its branches) cerebral infarctions in several arterial territories involving both hemispheres, or in the same hemisphere, or in both anterior and posterior circulation, symptomatic or not
    2. or a single cerebral infarction and systemic emboli (e.g., renal, splenic, hepatic or mesenteric infarction, peripheral emboli in arm or leg), symptomatic or not
    3. or any ischemic stroke with dilation of atrium (>34 mL/m²) or left atrial spontaneous echocardiographic contrast or LAA velocities \< 40 cm/sec or pro BNP > 400 pg/mL or (LVEF) \< 40% or supraventricular extrasystole ≥ 400/24 h or longest "atrial run" ≥ 20 beats on telemetry
    4. or age ≥80 year-old and a single infarction
  4. and a plan to detect atrial fibrillation with, long term Holter , wearing device or implantable loop recorder
  5. with a Rankin score equal or less than 4
  6. patient has signed an
  7. Patient is affiliated to a social security.

Exclusion criteria

Exclusion Criteria:

  1. Patients with a known cause of stroke, using ASCOD classification A1, C1, S1, O1, D1
  2. Symptomatic brain hemorrhage (the mere presence of microbleeds on gradient echo imaging is not an exclusion criteria)
  3. Uncontrolled hypertension (following the judgment of the investigator)
  4. Clear indication to anticoagulant or antiplatelet therapy
  5. to anticoagulant or antiplatelet therapy
  6. Intercurrent disease that may interfere with evaluation of the primary end-point or that may prevent follow-up study visits
  7. Participation in another interventional clinical trial.
  8. Under in case of
  9. Patient under guardianship or curatorship
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
1,148 participants (estimated)

Study arms

  • Experimental
    Therapeutic anticoagulation

    Choice of the investigator, VKA with target INR 2-3, or apixaban, rivaroxaban or dabigatran)

    Drug: Apixaban

  • Active comparator
    Aspirin 75-300 mg/day

    Aspirin is the standard of care treatment.

    Drug: Aspirin

Interventions

  • Patients who have had an ischemic stroke will receive either an anticoagulant or aspirin according to their randomization arm.

    Also known as: AVK, rivaroxaban, dabigatran

  • Aspirin is used as the standard of care

06

What researchers measure

Primary outcomes

  1. Occurrence of fatal or nonfatal ischemic stroke, or peripheral emboli (even if asymptomatic) [peripheral emboli: emboli in arm or leg, new renal, splenic, hepatic, mesenteric infarction]

    Evaluate two commonly used antithrombotic treatment strategies in patients with recent ischemic stroke and at high risk of atrial fibrillation.

    Time frame: During the 12 month follow-up

Secondary outcomes

  1. Sensitivity (percentage of true positives) in detecting AF

    Yield and comparative rates of atrial fibrillation discovered using various tools (Holter-ECG monitoring device, loop recorder (wearing or implantable monitoring device).

    Time frame: long term using various tools (3 weeks)

  2. The Occurrence of: Recurrent fatal or nonfatal ischemic stroke, any stroke, any stroke or TIA or vascular death

    Evaluate two commonly used antithrombotic treatment strategies in patients with recent ischemic stroke and at high risk of atrial fibrillation.

    Time frame: During the 12 month follow-up

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2025 (actual). Primary completion is estimated for Dec 2028, 42 months after the start.

Of 84 non-industry phase 4 interventional studies under Stroke, half reached primary completion within 57 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 95. This study's planned 42 months is below that.

Counting every sponsor, half of 90 studies reached it within 57 months; a quarter within 29 and three quarters within 95.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 14, 2024
First posted
Jul 5, 2024
StartActual
Jun 18, 2025
Primary completionEst.
Dec 18, 2028
CompletionEst.
Dec 18, 2028
Last update
Jun 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 5, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06486792
Responsible party
Sponsor
First posted
Jul 5, 2024
Start date
Jun 18, 2025
Primary completion
Dec 18, 2028 (estimated)
Completion
Dec 18, 2028 (estimated)
Last update
Jun 5, 2026

Study contacts

Philippa Lavallée, PhD
Contact
philippa.lavallee@aphp.fr
1 40 25 87 25 ext. +33

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Apixaban

Start the discussion